病毒性肝炎患者血清载脂蛋白B含量的变化

FINDING OUT HYPERCOAGULATION INDEX AND ITS CLINICAL SIGNIFICANCE

用免疫电泳法测定108例急性病毒性肝炎患者和56例非肝炎对照组的血清载脂蛋白B(ApoB)含量,其均值分别为58.95mg/dl(SD=14.48)和81.75mg/dl(SD=12.29),两组差异有高度显著性(P<0.001);肝炎组异常率为79.6%。108例中急性肝炎62例,慢性迁延性和慢性活动性肝炎46例,血清ApoB含量分别为61.43mg/dl(SD=17.49)和55.6mg/dl(SD=8.01),与对照组比较,差异有高度显著性(P<0.001),两者的异常率分别为74.19%和79%。急、慢性肝炎组间亦有差别(P<0.05)。显示血清ApoB测定可望成为了解肝功及预后判断的一项有意义的指标。

Based on 6 parameters of platelet aggregation ratio, factor Ⅷ related antigen, concentration of fibrinoconection, plasminogen, antithrombin Ⅲantigen and its activity, and evaluating changes of hemostasis and thrombosis in normal adults and in patients with thrombosis and hypercoagulable state (HCS), hypercoagulation indexes (HCI) were fulfilled statistically. The HCIs in 38 adult subjects, 19 patients with thrombosis and 32 patients with HCS were 0.01±1.46, 6.65±1.60 and 3.80±1,10 (±SD), and there were significant differences each other (P<0.01). A preliminary study on the above results suggests that HCI is a useful standard for evaluating total balance of coagulation-anticoagulation and fibr nolysis in the human body. The more severe hypercoagulation is, the more HCI increases.